TheEdgeResearch
Home / Stocks / VRXA

Veraxa Biotech Holding AG (VRXA)

NASDAQ Healthcare Biotechnology
$1.04 ▲ +0.97%
Market Cap
$147.1M
Sector
Healthcare
Industry
Biotechnology
Beta
0.26
52-Wk Range
0.9-27.36
CEO
Christoph Antz
Country
DE
Currency
USD

Veraxa Biotech Holding AG operates in the Biotechnology industry of the Healthcare sector, headquartered in Heidelberg, ZH, DE. The stock last traded at $1.04, up 0.97% on the session, giving a market capitalisation of $147.1M. Its beta of 0.26 implies it has historically moved less than the broad market.

Company profile
Exchange
NASDAQ
Employees
8
IPO date
2026-06-09
Headquarters
Heidelberg, ZH, DE
About Veraxa Biotech Holding AG

Veraxa Biotech AG develops antibody-based therapeutics and antibody-drug conjugates for cancer treatment. The company develops antibody-based therapeutics, including antibody-drug conjugates and bispecific antibody formats, and offers a proprietary technology platform for functional antibody screening and bioconjugation. Its product pipeline includes drug candidates such as ADCs and BITACs, with some in clinical development, and it provides partnership models for collaborative development from target identification to antibody and ADC creation. The company was founded in 2021 and is based in Heidelberg, Germany.

More research on VRXA
VRXA technical analysis VRXA TheEdge Score Compare against peers
Open full interactive analysis & DCF →